|
|
 |
 |
| |
|
|
|
|
 |
| |
 |
|
An IV respiratory quinolone solution containing levofloxacin (500 mg/100 ml),
with enhanced antibacterial activity against a wide range of Gram-positive and
Gram-negative bacteria, including Streptococcus pneumoniae and Pseudomonas
aeruginosa. Approved for use in a wide range of infectious conditions,
including CAP due to MDRSP, Nosocomial Pneumonia, SSSI (complicated or
uncomplicated) and UTIs (complicated or uncomplicated). The adult daily dose is
250-750 mg, given once daily.
Detailed Product Information >>
|
|
|
|
 |
|
An oral quinolone preparation with 99% bioavailability
containing levofloxacin, with a two-fold stronger activity than ofloxacin and
antibacterial activity against a wide range of Gram-positive and Gram-negative
bacteria. The adult daily dosage can be given from 200 mg to 600 mg in 2 or 3
divided doses.
Detailed Product Information >>
|
| |
|
|
 |
|
In addition to the existing 100 mg tablets, the new 250 mg formulation offers
dosing convenience for conditions where Cravitâ 250 mg to 750 mg Once-Daily is
indicated. These conditions include: Acute Bacterial sinusitis (500mg QD x
10-14 days or 750mg QD x 5 days), ABECB (500mg QD), CAP (500mg QD x 7-14 days,
or 750mg QD x 5 days), Nosocomial Pneumonia (750mg QD x 7-14 days), c-UTI
(250mg QD), pyelonephritis (250mg QD), and SSTI (250mg QD or 500mg QD-BID)
Detailed Product Information >>
|
| |
|
 |
|
|
|
 |
 |
|
An oral quinolone preparation containing ofloxacin, an
antibacterial agent with a broad-spectrum activity against various
Gram-positive and Gram-negative bacteria. The adult daily dose is 300 mg to 600
mg in 2 or 3 divided doses. Tarivid Tablets are available in 100 mg and 200 mg
units.
Detailed Product Information >>
|
|
|
|
 |
|
A quinolone ear solution containing ofloxacin (0.3%, 3 mg/mL), a broad-spectrum
antibacterial agent indicated for Gram-positive and Gram-negative otitis media
and otitis externa. The adult dose for OE is 5-10 drops once-daily for 7 days,
and for OM is 6-10 drops twice daily.
Detailed Product Information >>
|
| |
|
|
|
|
|
 |
 |
|
An IV preparation of tranexamic acid (5% or 10% w/v solution)
indicated in haemorrhagic, allergic and inflammatory conditions involving
hyperfibrinolysis, such as abnormal bleeding in surgery, O&G, urology, or
erythema. The adult daily dosage is 250-500 mg in 1-2 injections, or 500-2500
mg by IV drip infusion during and after surgery.
Detailed Product Information >>
|
|
|
|
 |
|
An oral preparation of tranexamic acid (500 mg/tab), indicated
in haemorrhagic, allergic and inflammatory conditions involving
hyperfibrinolysis, such as abnormal bleeding in surgery, O&G, urology, or
erythema. The adult daily dosage is 2-4 tablets in 3 or 4 portions.
Detailed Product Information >>
|
|
|
|
 |
|
An oral preparation of tranexamic acid (250 mg/cap), indicated
in haemorrhagic, allergic and inflammatory conditions involving
hyperfibrinolysis, such as abnormal bleeding in surgery, O&G, urology, or
erythema. The adult daily dosage is 3-8 capsules in 3 or 4 portions.
Detailed Product Information >>
|
| |
|
|
|
|
|
|
 |
| |
|
1. Diagnogreen Injection
2. ATP Injection
3. Metilon Injection
4. ATP Tablet
5. Gammalon Tablets 250 mg
|
|
|
| |
 |
|
|
